[New Lipid-lowering Agents]

Area of Science:

• Cardiology
• Pharmacology
• Public Health

Background:

• Atherosclerotic cardiovascular disease (ASCVD) is a leading cause of death and disability.
• Elevated low-density lipoprotein-cholesterol (LDL-C) is a well-established causal factor in ASCVD development.
• Statins are a cornerstone therapy for ASCVD prevention by lowering LDL-C, but limitations exist.

Purpose of the Study:

• To highlight the need for additional or alternative LDL-C lowering therapies.
• To address limitations of statin therapy, including variable response, side effects, and persistent high LDL-C in high-risk patients.
• To acknowledge ongoing research into novel lipid-lowering drug targets.

Main Methods:

• Review of epidemiological, genetic, and clinical trial data on LDL-C and ASCVD.
• Analysis of statin therapy efficacy, safety, and limitations.
• Identification of unmet needs in ASCVD risk reduction.
• Overview of current clinical trials investigating new therapeutic targets.

Main Results:

• Despite statin effectiveness, many high-risk patients have residual high LDL-C levels.
• Individual responses to statins vary significantly, and side effects can impact adherence.
• Novel therapeutic strategies targeting triglycerides and lipoprotein (a) are under investigation for potential cardiovascular benefits.

Conclusions:

• There is a substantial need for LDL-C lowering therapies beyond statins.
• Addressing residual cardiovascular risk in high-risk populations requires innovative treatment approaches.
• Future research is focused on developing and evaluating new drug classes for comprehensive lipid management.